An-hui Gao

State Key Laboratory Of Drug Research
Shanghai, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Author Correction: Discovery of toxoflavin, a potent IRE1α inhibitor acting through structure-dependent oxidative inhibition.

Author Correction: Discovery of toxoflavin, a potent IRE1α inhibitor acting through structure-dependent oxidative inhibition.

Journal: Acta pharmacologica Sinica
Published: August 04, 2023

Discovery of toxoflavin, a potent IRE1α inhibitor acting through structure-dependent oxidative inhibition.

Discovery of toxoflavin, a potent IRE1α inhibitor acting through structure-dependent oxidative inhibition.

Journal: Acta pharmacologica Sinica
Published: January 05, 2022

Downregulation of c-Myc expression confers sensitivity to CHK1 inhibitors in hematologic malignancies.

Downregulation of c-Myc expression confers sensitivity to CHK1 inhibitors in hematologic malignancies.

Journal: Acta pharmacologica Sinica
Published: December 26, 2020

Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma.

Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma.

Journal: Acta pharmacologica Sinica
Published: December 07, 2020

Diffuse large B-cell lymphoma with low 18F-fluorodeoxyglucose avidity features silent B-cell receptor signaling.

Diffuse large B-cell lymphoma with low 18F-fluorodeoxyglucose avidity features silent B-cell receptor signaling.

Journal: Leukemia & lymphoma
Published: February 25, 2020

Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma.

Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma.

Journal: Acta pharmacologica Sinica
Published: February 24, 2020

Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.

Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles.

Journal: European journal of medicinal chemistry
Published: October 25, 2018

Novel CHOP activator LGH00168 induces necroptosis in A549 human lung cancer cells via ROS-mediated ER stress and NF-κB inhibition.

Novel CHOP activator LGH00168 induces necroptosis in A549 human lung cancer cells via ROS-mediated ER stress and NF-κB inhibition.

Journal: Acta pharmacologica Sinica
Published: September 25, 2015

Azoxystrobin, a mitochondrial complex III Qo site inhibitor, exerts beneficial metabolic effects in vivo and in vitro.

Azoxystrobin, a mitochondrial complex III Qo site inhibitor, exerts beneficial metabolic effects in vivo and in vitro.

Journal: Biochimica et biophysica acta
Published: November 13, 2013

Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth.

Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth.

Journal: Biochimica et biophysica acta
Published: June 15, 2013

Fluevirosines A-C: a biogenesis inspired example in the discovery of new bioactive scaffolds from Flueggea virosa.

Fluevirosines A-C: a biogenesis inspired example in the discovery of new bioactive scaffolds from Flueggea virosa.

Journal: Organic letters
Published: December 19, 2012

Discovery and optimization of 2,4-diaminoquinazoline derivatives as a new class of potent dengue virus inhibitors.

Discovery and optimization of 2,4-diaminoquinazoline derivatives as a new class of potent dengue virus inhibitors.

Journal: Journal of medicinal chemistry
Published: March 28, 2012
Showing 1-12 of 12

Last Updated: 09/26/2026